Per Share Amounts

9 Months Ended

Sep. 30, 2020

Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. Based on the guidance provided in accordance with ASC 260 Earnings Per Share (“ASC 260”), potentially dilutive common stock equivalents, such as diluted stock options, are not considered when their inclusion in reporting earnings per share would be dilutive to reported losses incurred per share. Because the Company reported a loss for the three and nine-month periods ended September 30, 2020, the potentially dilutive effects of approximately 10,000, of the Company’s stock options and 31,000 of the Company's unvested restricted stock awards were not considered for the reporting periods. The computation for the three and nine-month periods ended September 30, 2019 excluded approximately 513,000, of the Company's stock options because the exercise price of the options was higher than the average market price during those periods.

During the three-month period ended June 30, 2020, the Company appointed Raymond C. Stachowiak as Interim President and Chief Executive Officer (“Interim CEO”). As part of his Offer Letter, the Interim CEO was granted 50,000 restricted stock awards that vested in full on August 3, 2020. In addition, since the Interim CEO continued to serve the Company after August 3, 2020, he was granted additional restricted stock awards totaling 10,000 common shares, which vest in full at the end of each 30-day period after August 3, 2020. On October 1, 2020 the Interim CEO was appointed the Chief Executive Officer (“CEO”). For the three and nine-month periods ended September 30, 2020, 60,000 restricted stock awards were issued to the CEO and fully vested. During the three-month period ended September 30, 2020, Ernest R. Bates, Senior Vice President, Sales and Business Development, International Operations, was awarded 10,000 restricted stock awards, which will vest on December 31, 2020.

On March 31, 2020, the Company’s Award Agreements (as defined below) expired and the unvested performance share awards were returned to the Company’s stock incentive plan - see Note 7 for further discussion. Based on the guidance provided in accordance with ASC 260, the weighted average common shares for basic earnings per share, for the three and nine-month periods ended September 30, 2019, excluded the weighted average impact of the unvested performance share awards. These awards were legally outstanding but not deemed participating securities and therefore were excluded from the calculation of basic earnings per share. The unvested shares were also excluded from the denominator for diluted earnings per share because they were considered contingent shares not deemed probable as of September 30, 2019.

The following table sets forth the computation of basic and diluted earnings per share for the three and nine-month periods ended September 30, 2020 and 2019:


	Three Months ended September 30,				Nine Months ended September 30,
	2020		2019		2020		2019
Net (loss) income attributable to American Shared Hospital Services	$	(209,000)	$	165,000	$	(827,000)	$	466,000

Weighted average common shares for basic earnings per share	6,049,000		5,889,000		6,060,000		5,899,000
Diluted effect of stock options and restricted stock awards	—		19,000		—		18,000
Weighted average common shares for diluted earnings per share	6,049,000		5,908,000		6,060,000		5,917,000

Basic (loss) earnings per share	$	(0.03)	$	0.03	$	(0.14)	$	0.08
Diluted (loss) earnings per share	$	(0.03)	$	0.03	$	(0.14)	$	0.08